Journals / Türk Dermatoloji Dergisi / 2016 / Cilt: 10 - Sayı: 2

Retrospective Evaluation of Risk Factors and Response in Treatment among Hospitalized Patients with Lower-Extremity Cellulitis

Hastaneye Yatırılarak Tedavi Edilen Alt Ekstremite Yerleşimli Selülit Hastalarının Risk Faktörleri ve Tedaviye Yanıt Açısından Retrospektif Olarak Değerlendirilmesi

Pages
59–64
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Relatively longer duration of treatment in our patients has been attributed to the facts that being a tertiary medical center, dealing mostly with therapy resistant and high risk patients of cellulitis or antibiotic resistance in our country.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To reveal the risk factors for lower-extremity cellulitis, to investigate the role of risk factors on the treatment, and to have knowledge about treatment efficiency and the optimal duration of therapy in patients on parenteral antibiotic therapy.Methods: Potential risk factors, therapies used during hospitalization, outcomes of therapies and follow-up data of 46 patients hospitalized in the Department of Dermatovenereology of İstanbul Medical Faculty of İstanbul University with lowerextremity cellulitis between years 2009 and 2014 were investigated retrospectively.Results: Tinea pedis (n=19), diabetes mellitus (n=12), by-pass surgery (n=6), and chronic lymphedema of the legs (n=5) were detected as main risk factors.
📊
Key Findings & Data:Thirty nine of the patients (84.8%) were treated with parenteral ampicillin-sulbactam.
💡
Conclusion & Impact:Relatively longer duration of treatment in our patients has been attributed to the facts that being a tertiary medical center, dealing mostly with therapy resistant and high risk patients of cellulitis or antibiotic resistance in our country.
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To reveal the risk factors for lower-extremity cellulitis, to investigate the role of risk factors on the treatment, and to have knowledge about treatment efficiency and the optimal duration of therapy in patients on parenteral antibiotic therapy.Methods: Potential risk factors, therapies used during hospitalization, outcomes of therapies and follow-up data of 46 patients hospitalized in the Department of Dermatovenereology of İstanbul Medical Faculty of İstanbul University with lowerextremity cellulitis between years 2009 and 2014 were investigated retrospectively.Results: Tinea pedis (n=19), diabetes mellitus (n=12), by-pass surgery (n=6), and chronic lymphedema of the legs (n=5) were detected as main risk factors. Improvement with systemic therapy was seen in all patients except one patient who was lost to follow-up. Thirty nine of the patients (84.8%) were treated with parenteral ampicillin-sulbactam. The mean duration of parenteral antibiotic therapy was 17.7±12.4 (median: 14) days. In 11 patients (32.4%), recurrence was detected, during an average follow-up of 2 years. There was a significant correlation between tinea pedis and recurrence.Conclusion: Tinea pedis and chronic lymphedema were main risk factors for multiple attacks. Parenteral antibiotic treatment mostly used as the single drug regimen with ampicillinsulbactam was highly effective. Relatively longer duration of treatment in our patients has been attributed to the facts that being a tertiary medical center, dealing mostly with therapy resistant and high risk patients of cellulitis or antibiotic resistance in our country.

Özet

Amaç: Bacak yerleşimli selülit olgularında risk faktörlerinin ortaya çıkarılması, risk faktörlerinin tedaviye etkisinin araştırılması ve parenteral antibiyotik tedavisi uygulanan hastalarda tedavi etkinliği ve uygun tedavi süresi konusunda fikir sahibi olunmasıdır.Yöntemler: İstanbul Üniversitesi İstanbul Tıp Fakültesi, Deri ve Zührevi Hastalıkları Anabilim Dalı'nda, 2009-2014 yılları arasında yatırılarak tedavi edilen alt ekstremite selüliti tanılı 46 hastada enfeksiyon açısından olası risk faktörleri, yatış sırasında kullanılan tedaviler, sonuçları ve tedavi sonrası izlemeye alınan hastalarda nüks gelişimi retrospektif olarak değerlendirildi.Bulgular: Tinea pedis (n=19), diabetes mellitus (n=12), baypas cerrahisi (n=6) ve kronik lenfödem (n=5) risk faktörleri olarak saptandı. Takibi olmayan bir hasta dışındakilerin tümünde tam iyileşme saptandı. Hastaların 39'unda (%84,8) tek başına parenteral ampisilin-sulbaktam kullanıldı. İntravenöz antibiyotik tedavi süresi ortalama 17,7±12,4 gün (ortanca: 14 gün) olarak tespit edildi. Ortalama 2 yıllık izlem süresinde 11 hastada (%32,4) nüks saptandı ve tinea pedis ile nüks arasında anlamlı ilişki bulundu.Sonuç: Tinea pedis ve kronik lenfödem birden fazla atak oluşumunda risk faktörleri olarak saptandı. Parenteral antibiyotik tedavisi, bu amaçla da "tek başına ampisilin-sulbaktam" en sık kullanılan tedavi şekli olup alt ekstremite selülitinde çok yüksek oranda etkili bulundu. İyileşme için gerekli ortalama süre başka çalışmalara göre biraz uzun bulundu. Çalışmanın çoğunlukla dirençli ve komplike hastaların başvurduğu üçüncü basamak bir tedavi merkezinde gerçekleşmiş olması veya ülkemizdeki olası bir antibiyotik direnci bu sonuçta rol oynamış olabilir.

🔖

Cite This Article

BAYKAL, C., MEHDİ, L., EKİNCİ, A. P. (2022). Retrospective Evaluation of Risk Factors and Response in Treatment among Hospitalized Patients with Lower-Extremity Cellulitis. Türk Dermatoloji Dergisi, Cilt: 10 - Sayı: 2, 59–64. https://ajindex.com/articles/621609

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Bhagavatula M, Powell C. Common superficial skin infections and infestations. Paediatr Child Health 2011;21:132-6.
  2. Wolff K, Goldsmith LA, Katz SI. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York: McGraw-Hill Companies; 2008. p.1689-731.
  3. Phoenix G, Das S, Joshi M. Diagnosis and management of cellulitis. BMJ 2012;345:4955. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59:10-52.
  4. Gottlieb T, Atkins BL, Shaw DR. Soft tissue, bone and joint infections. Med J Aust 2002;176:609-15.
  5. Turhan Ö, Saba R, Öngüt G, ve ark. Bir üniversite hastanesinde izlenen 68 selülit olgusunun değerlendirilmesi. Klimik Dergisi 2006;19:114-6.
  6. Dong SL, Kelly KD, Oland RC, et al. ED management of cellulitis: a review of five urban centers. Am J Emerg Med 2001;19:535-40.
  7. Drago F, Gasparini G, Signori A, et al. Dermatological consultations in an observation unit of an emergency department in Italy. J Eur Acad Dermatol Venereol 2015;29:973-80.
  8. Karppelin M, Siljander T, Vuopio-Varkila J, et al. Factors predisposing to acute and recurrent bacterial non-necrotizing cellulitis in hospitalized patients: a prospective case-control study. Clin Microbiol Infect 2010;16:729-34.
  9. Picard D, Klein A, Grigioni S, Joly P. Risk factors for abscess formation in patients with superficial cellulitis (erysipelas) of the leg. Br J Dermatol 2013;168:859-63.
  10. Campbell S, Burton-MacLeod R, Howlett T. A cellulitis guideline at a community hospital-we can reduce costs by standardizing care. Australasian J Paramedicine 2009;7:990329. Pavlotsky F, Amrani S, Trau H. Recurrent erysipelas: risk factors. J Dtsch Dermatol Ges 2004;2:89-95. http://www.tuik.gov.tr. Cox NH. Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: a series with community follow-up. Br J Dermatol 2006;155:947-50. http://www.turkendokrin.org/files/file/TURDEP_II_2011.pdf.
  11. Carratala J, Roson B, Fernandez-Sabe N, et al. Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microbiol Infect Dis 2003;22:151-7.
  12. Suaya JA, Eisenberg DF, Fang C, Miller LG. Skin and soft tissue infections and associated complications among commercially insured patients aged 0-64 years with and with out diabetes in the U.S. PLoS ONE 2013;8:60057. Björnsdottir S, Gottfredsson M, Thorisdottir AS, et a